Direct effects of DPP-4 on immune cells and indirect effects through GLP-1-dependent and GLP-1-independent pathways suggest that enzyme inhibition may have beneficial effects beyond glycaemic control, which may contribute to CKD and CVD outcomes [71]. Here, GCG is linked to chronic kidney disease.